— Sarepta Therapeutics, Inc. (NASDAQ: SRPT) reported a loss of $1.57 per share in the fourth quarter of 2019, vs $1.86 per share loss expected.
— Q4 revenue rose 19% to $100.1 million, vs. $98.8 million expected. Results were helped by an increase in demand for EXONDYS 51 in the U.S.
— Appointed biotech executive John C. Martin to Board of Directors. He is a former Gilead CEO.
— SRPT shares ended Wednesday’s regular trading session down 1.14%.
Listen to on-demand earnings calls and hear how management responds to analysts’ questions
Most Popular
360 DigiTech (NASDAQ: QFIN) Q2 2021 Research Summary
The pandemic-induced financial uncertainties have changed the dynamics of the consumer lending market. Customers are being drawn to online lending platforms that provide easy access to credit on convenient terms
Banxa founder Domenic Carosa: Crypto industry seeing huge HNI interest
While bitcoin and other digital currencies have seen a fair share of ups and downs so far this year, investor interest in cryptocurrency has grown undeniably during this period. The
Oracle (ORCL) Q4 earnings, revenue beat Street view
Software giant Oracle Corporation (NYSE: ORCL) reported a 28% growth in fourth-quarter earnings, aided by an increase in revenues. The results also topped Wall Street's prediction. At $11.2 billion, revenues
